Pediatric asthma: An approach to pharmacogenetics analysis

Chest

Volumn 123, Issue 3 SUPPL., 2003, Pages 434S-438S

  Szefler, Stanley J ^a  

^a NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE DIPROPIONATE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CORTICOSTEROID; FLUTICASONE PROPIONATE; IMMUNOGLOBULIN E; INTERLEUKIN 13; INTERLEUKIN 4; LEUKOTRIENE RECEPTOR BLOCKING AGENT; METHACHOLINE; NEDOCROMIL; PLACEBO;

AIRWAY; ALLERGIC RHINITIS; ASTHMA; ATOPIC DERMATITIS; CLINICAL FEATURE; CLINICAL TRIAL; COHORT ANALYSIS; CONFERENCE PAPER; DEVICE; DISEASE CONTROL; DISEASE COURSE; DISEASE SEVERITY; DRUG DELIVERY SYSTEM; EOSINOPHILIA; FORCED EXPIRATORY VOLUME; GENETIC POLYMORPHISM; GROWTH RETARDATION; HOSPITALIZATION; HUMAN; INFLAMMATION; LUNG; ORGAN GROWTH; OSTEOPOROSIS; PEDIATRICS; PHARMACOGENETICS; PRACTICE GUIDELINE; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; WHEEZING;

EID: 0037338507     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (24)

1. Global Initiative for Asthma. Global strategy for asthma management and prevention: NHLBI/NIH workshop report. Bethesda, MD: National Institutes of Health, National Heart, Lung, and Blood Institute, 1995; publication No. 95-3659
2. National Asthma Education and Prevention Program. Expert panel report 2: Guidelines for the diagnosis and management of asthma. Bethesda, MD: National Institutes of Health, National Heart, Lung, and Blood Institute, 1997; publication No. 97-4051
3. Agertoft L, Pedersen S. Effects of long term treatment with an inhaled corticosteroid on growth and pulmonary function in asthmatic children. Respir Med 1994; 88:373-381
4. Leung DYM, Spahn JD, Szefler SJ. Steroid-resistant asthma: new insights and implications for management. In: Szefler SJ, Leung DYM, eds. Severe asthma: a multidisciplinary approach. 2nd ed. New York, NY: Marcel Dekker, 2001; 597-619
5. Peat JK. Asthma: a longitudinal perspective. J Asthma 1998; 35:235-241
6. Zeiger RS, Dawson C, Weiss S, et al. Relationships between duration of asthma and asthma severity among children in the Childhood Asthma Management Program (CAMP). J Allergy Clin Immunol 1999; 103:376-387
7. Szefler SJ, Eigen H. Budesonide inhalation suspension: a nebulized corticosteroid for persistent asthma. J Allergy Clin Immunol 2002; 109:730-742
8. Szefler SJ, Martin RJ, and the Asthma Clinical Research Network. Evaluation and comparison of inhaled steroids. In: Schleimer PM, O'Byrne PM, Szefler SJ, et al, eds. Airway activity and selectivity of inhaled steroids in asthma: mechanisms, models of evaluation, and clinical impacts. Lung biology in health and disease series. New York, NY: Marcel Dekker, 2002; 389-418
9. Spahn JD, Szefler SJ. Childhood asthma: new insights into management. J Allergy Clin Immunol 2002; 109:3-13
10. Phelan PD, Robertson CF, Olinsky A. The Melbourne Asthma Study: 1964-1999. J Allergy Clin Immunol 2002; 109:189-194
11. Martinez FD. Development of wheezing disorders and asthma in preschool children. Pediatrics 2002; 109:362-367
12. Castro-Rodriguez JA, Holberg CJ, Wright AL, et al. A clinical index to define risk of asthma in young children with recurrent wheezing. Am J Respir Crit Care Med 2000; 162:1403-1406
13. Long-term effects of budesonide or nedocromil in children with asthma. The Childhood Asthma Management Program Research Group. N Engl J Med 2000; 343:1054-1063
14. Jenkins HA, Szefler SJ, Covar RA, et al. New insight into the clinical characteristics of adults vs children with severe asthma [abstract]. J Allergy Clin Immunol 2002; 109:1100A
15. Martin RJ, Szefler SJ, Chinchilli VM, et al. Systemic effect comparisons of six inhaled corticosteroid preparations. Am J Respir Crit Care Med. 2002; 165:1377-1383
16. Szefler SJ, Richard J, Martin RJ, et al. Significant variability in response to inhaled corticosteroids for persistent asthma. J Allergy Clin Immunol 2002; 109:410-418
17. Marsh DG, Neely JD, Breazeale DR, et al. Linkage analysis of IL4 and other chromosome 5q31.1 markers and total serum immunoglobulin E concentrations. Science 1994; 264:1152-1156
18. Borish L, Mascali JJ, Klinnert M, et al. SSC polymorphisms in interleukin genes. Hum Mol Genet 1994; 3:1710 [erratum, Hum Mol Genet 1995; 4:974]
19. Rosenwasser LJ, Klemm DJ, Dresback JK, et al. Promoter polymorphisms in the chromosome 5 gene cluster in asthma and atopy. Clin Exp Allergy 1995; 25(Suppl 2):74-78; discussion 95-96
20. 1 in asthma. Am J Respir Crit Care Med 1999; 160:919-922
21. Hershey GK, Friedrich MF, Esswein LA, et al. The association of atopy with a gain-of-function mutation in the α subunit of the interleukin-4 receptor. N Engl J Med 1997; 337:1720-1725
22. Rosa-Rosa L, Zimmermann N, Bernstein JA, et al. The R576 IL-4 receptor α allele correlates with asthma severity. J Allergy Clin Immunol 1999; 104:1008-1014
23. Martinez FD. Maturation of immune responses at the beginning of asthma. J Allergy Clin Immunol 1999; 103:355-361
24. Spahn JD, Szefler SJ, Surs W, et al. A novel action of IL-13: induction of diminished monocyte glucocorticoid receptor-binding affinity. J Immunol 1996; 157:2654-2659